Login
$SPRB
$42.25 -$1.06 (2.45%) Live

$SPRB SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Biologics License Application (“BLA”) Submission for Tralesinidase Alfa Enzyme Replacement Therapy (“TA-ERT”) for the Treatment of MPS IIIB Remains on Track for December 2026 Amended Avenue Loan Agreement to Increase Tranche 2 Availabili...

14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected to Initiate in the Fou...

04 Aug 2026 SCHEDULE 13G/A
30 Jul 2026 SCHEDULE 13G
29 Jul 2026 Form 4: Quartel Adrian W, Chief Medical Officer

Granted 13,000 Restricted Stock Units

29 Jul 2026 Form 3: Quartel Adrian W, Chief Medical Officer

No securities owned

27 Jul 2026 SCHEDULE 13G
27 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 27, 2026, Spruce Biosciences, Inc. (the “Company”) appointed Adrian Quartel, M.D., FFPM, as the Company’s Chief Medical Officer, replacing Dr. Kirk Ways, who had been serving as the Company’s Interim Chief Medical Officer. Dr. Wa...

09 Jul 2026 Form 4: Szwarcberg Javier B., Director

Received 266 shares as a grant or award ($1.21K)

26 May 2026 Form 4: Spiegelman Daniel K, Director

Granted 1,700 Stock Option (Right to Buy)

26 May 2026 Form 4: Simpson Camilla V, Director

Granted 1,700 Stock Option (Right to Buy)

26 May 2026 Form 4: Grey Michael G, Director

Granted 1,700 Stock Option (Right to Buy)

26 May 2026 Form 4: Barretto-Ko Percival, Director

Granted 1,700 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support